BASF and B2B Cosmetics partner to enable individualized personal care products28 Jan 2019
B2B Cosmetics will contribute their Emuage technology, which has received the “Innovation Award” at the trade show Consumer Electronics Show (CES) in Las Vegas.
BASF and B2B Cosmetics have announced an exclusive, long-term strategic partnership in the field of personalized personal care products, including a strategic investment in B2B Cosmetics by BASF.
The French company B2B Cosmetics will contribute a unique personalization system, marketed under the name Emuage technology. BASF will bring in expertise in personal care solutions.
Individualization of personal care products is a global key trend. To meet this growing need, a combination of interdisciplinary know-how is required. Together, BASF and B2B Cosmetics will build upon their respective expertise to offer this inventive technology to the market.
The Emuage technology allows users to create their own individualized personal care products by simply choosing capsules, placing them into the machine and receiving the final product – for example for hair, sun or skin care.
Recently, B2B Cosmetics received the “Innovation Award” at the trade show Consumer Electronics Show (CES) in Las Vegas for their Emuage technology for the second consecutive year.
“BASF is very proud to partner with B2B Cosmetics,” says Robert Parker, Head of New Business Development at Care Chemicals, BASF. “We will be collaborating with B2B Cosmetics to further leverage their unique technology in the coming months. We expect that the partnership enables us to support the industry with a new approach for individualized personal care products.”
“B2B Cosmetics will benefit from BASF’s experience and latest developments into personal care ingredients. This co-operation will allow us to establish and commercialize the technology and the device,” says Grégoire Tutenuit, CEO of B2B Cosmetics.
B2B Cosmetics and BASF aim to introduce the technology to the market in 2019 in a phased approach around the world.
Eisai collaborates with University of Dundee on cancer drug discovery
10 Jul 2019
It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.Read more
Onyx Scientific makes strategic investment in commercial API licence
10 Jul 2019
Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.Read more
I Holland to share the science behind tool maintenance
9 Jul 2019
Proper maintenance - rather than replacement - of compression tooling will improve profitability.Read more
Catalent extends global commercial spray drying capabilities in Europe
9 Jul 2019
Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.Read more
Operations commence at Wasdell Group’s EU headquarters
8 Jul 2019
The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.Read more
Porvair Sciences launches first Drosophila ChIP kits
4 Jul 2019
Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.Read more
Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound
3 Jul 2019
Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties.Read more
Fresh data on protein interactions in Alzheimer’s disease
2 Jul 2019
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.Read more
Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe
2 Jul 2019
The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids.Read more
Novartis bolsters ophthalmic portfolio with acquisition of Xiidra
1 Jul 2019
Xiidra 5% is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation